Toronto Telegraph March 15, 2013
Completion rates for the human papillomavirus vaccine series across both genders continue to remain alarmingly low nearly seven years after its introduction, suggesting that better patient education and increased public vaccine financing programs are needed, according to new research from UTMB. The researchers report “startling” trends in a series of three separate studies published in Cancer, Human Vaccines & Immunotherapeutics and Vaccine. “This is the first generation with the opportunity to be vaccinated against the devastating cancers associated with HPV, but the majority are missing the opportunity,” said lead author Dr. Abbey Berenson. The news also appears in Bio-Medicine and Infection Control Today.